Insulet Corporation $PODD Shares Purchased by Caisse DE Depot ET Placement DU Quebec

Caisse DE Depot ET Placement DU Quebec lifted its stake in Insulet Corporation (NASDAQ:PODD) by 169.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 43,372 shares of the medical instruments supplier’s stock after purchasing an additional 27,254 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned about 0.06% of Insulet worth $11,390,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PODD. Dimensional Fund Advisors LP increased its stake in Insulet by 42.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 289,507 shares of the medical instruments supplier’s stock worth $75,588,000 after acquiring an additional 86,505 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Insulet by 0.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 202,728 shares of the medical instruments supplier’s stock worth $52,927,000 after acquiring an additional 744 shares during the last quarter. Integrated Wealth Concepts LLC increased its stake in Insulet by 39.1% during the fourth quarter. Integrated Wealth Concepts LLC now owns 3,562 shares of the medical instruments supplier’s stock worth $930,000 after acquiring an additional 1,001 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Insulet during the fourth quarter worth $371,000. Finally, Northern Trust Corp increased its stake in Insulet by 20.5% during the fourth quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier’s stock worth $192,881,000 after acquiring an additional 125,710 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on PODD shares. Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Raymond James Financial reaffirmed an “outperform” rating and issued a $360.00 price objective (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Oppenheimer lifted their price objective on Insulet from $312.00 to $324.00 and gave the company an “outperform” rating in a research note on Friday, May 9th. Wells Fargo & Company lifted their price objective on Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Finally, Truist Financial began coverage on Insulet in a report on Monday, June 16th. They issued a “buy” rating and a $365.00 target price for the company. Sixteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $332.71.

Insulet Stock Up 0.8%

Shares of NASDAQ PODD opened at $334.35 on Thursday. The company has a market capitalization of $23.53 billion, a price-to-earnings ratio of 101.63, a price-to-earnings-growth ratio of 2.78 and a beta of 1.35. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The business has a 50-day moving average of $302.59 and a two-hundred day moving average of $286.87. Insulet Corporation has a 1 year low of $191.77 and a 1 year high of $335.86.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s revenue was up 32.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.